Heart and Blood Pressure Study: The Effect of Aortic Impedance on Myocardial Relaxation

The Effect of Aortic Impedance on Myocardial Relaxation

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00204984

Enrollment

Registered

2005-09-20

Start date

2005-05-31

Completion date

2006-12-20

Last updated

2019-02-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

High Blood Pressure

Keywords

arterial stiffness, echocardiography, nesiritide

Brief summary

Does dilation of blood vessels (vasodilation), which decreases aortic stiffness, have a greater effect on heart myocardium relaxation (diastole) than vasodilation which affects mean pressure equally without improving aortic stiffness?

Detailed description

60 subjects, 30 with hypertension and 30 without will attend two visits to the GCRC. At each visit, pulsatile hemodynamics (by using tonometry-a non-invasive means to obtain arterial pressure tracings) and Doppler tissue imaging relaxation velocity (a measurement of myocardial relaxation obtained by echocardiography) data will be collected before and after administration of vasodilator medication. At the first visit, each patient will receive an oral dose of the vasodilator hydralazine (does not effect aortic stiffness), and at the second visit each patient will receive intravenous nesiritide (does effect aortic stiffness). The relationship between timing of the reflected pulse wave and myocardial relaxation velocity will be studied at baseline and following administration of each vasodilator to determine if changing aortic stiffness has an impact on myocardial relaxation.

Interventions

DRUGoral hydralazine and intravenous nesiritide

vasodilators

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

BASIC_SCIENCE

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

65 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Subjects over the age of 65

Exclusion criteria

* Have known or suspected coronary artery disease * Have known or suspected left ventricular dysfunction * Have significant valvular, infiltrative, pericardial, or congenital heart disease * Have a resting systolic blood pressure \< 100 mmHg * Have had an adverse reaction to nesiritide or hydralazine * Have a serum creatinine \> 2 mg/dl at Visit 1

Design outcomes

Primary

Measure	Time frame
heart myocardium relaxation (diastole)	before and after administration of vasodilator medication

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 23, 2026